Thrombocytosis Treatment: Risk-Stratified Approach Based on Etiology
Primary vs. Secondary Thrombocytosis
- Reactive (Secondary): Infection, inflammation, iron deficiency, splenectomy, rebound. Treat the underlying cause; platelets normalize. Thrombotic risk is low.
- Clonal (Primary/Myeloproliferative): Essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), CML. Requires disease-specific therapy.
Management by Risk (Essential Thrombocythemia Example)
| Risk Category | Criteria | Therapy |
|---|---|---|
| Low | <60 years, no thrombosis, JAK2− | Observation ± low-dose aspirin |
| Intermediate | >60 years or JAK2+ | Aspirin + cytoreduction (hydroxyurea) |
| High | Prior thrombosis | Aspirin + hydroxyurea ± interferon-α |
Other MPNs
- PV: Phlebotomy (Hct <45% men, <42% women) + aspirin ± hydroxyurea.
- CML: TKI (imatinib, nilotinib).
- PMF: JAK inhibitor (ruxolitinib) for symptoms/splenomegaly.
Extreme Thrombocytosis (>1,000–1,500×10⁹/L)
Acquired von Willebrand syndrome → bleeding risk. Plateletpheresis for acute symptoms; urgent cytoreduction.
Blood Disorders - Related Articles
- Causes of Vomiting Blood (Hematemesis): Symptoms and Treatments
- Inspiring Blood Donation Slogans That Motivate Action
- O Negative Blood: Universal Donor Compatibility Explained
- Losing a Quart of Blood: Physiologic Consequences & Emergency Response
- Understanding Blood Clots: Symptoms, Diagnosis & Treatment
- Understanding Thrombocytopenia: Symptoms, Diagnosis & Causes
- Understanding Elevated White Blood Cell Counts (Leukocytosis)
